UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

______________

FORM 8-K

______________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~January~~February 2920, 2015

VAPORIN, INC.

(Exact name of registrant as specified in its charter)

Delaware	000-55132	45-5215796
(State or Other Jurisdiction	(Commission	(I.R.S. Employer
of Incorporation)	File Number)	Identification No.)

4400 Biscayne Boulevard

Miami, FL 33137

(Address of Principal Executive Office) (Zip Code)

(305) 576-9298

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 15.0107 Submission ~~Entry~~of ~~into~~Matters to a ~~Material~~Vote ~~Definitive~~of ~~Agreement~~Security Holders.

On ~~January~~February 2920, 2015, ~~Vaporin,~~at ~~Inc. (the “Company”) was issued~~ a ~~$350,000~~Special ~~note~~Meeting ~~by Vapor Corp. (“Borrower”) in consideration for a loan~~ of ~~$350~~Shareholders,~~000. The~~ ~~note accrues interest on~~ the ~~outstanding~~shareholders ~~principal at an annual rate~~ of ~~12%. The principal and accrued interest on the note is due and payable on January 29~~Vaporin, ~~2016 (the “Maturity Date”)~~Inc. If ~~the~~approved ~~merger~~all between the Company and the Borrower (“Merger”) does not close by May 31, 2015 (the “End Date”), the Maturity Date will accelerate and become due June 1, 2015. Additionally, if the Merger does not close by the End Date or in the event of ~~a default by~~ the ~~Borrower,~~proposals ~~the~~put ~~note will be convertible into the Borrower’s common stock at 85% of the Borrower’s closing price on May 29, 2015. If the merger closes prior~~ to ~~the~~a ~~End Date, the note shall not be convertible~~vote. The ~~note~~final ~~shall~~vote ~~not~~results bewere ~~convertible until such time~~ as ~~the Nasdaq Stock Market (“Nasdaq”) approves the issuance of the shares underlying the note.~~follows:

By1. ~~February~~Approval ~~28,~~of ~~2015,~~ the ~~Borrower~~Agreement isand ~~required~~Plan ~~to submit a Listing~~ of ~~Additional~~Merger, ~~Shares~~dated ~~notification~~as ~~form with Nasdaq and take other actions required by Nasdaq in order to receive approval~~ of ~~the~~december ~~issuance~~17, of2014, ~~the~~between ~~shares~~Vapor ~~underlying the note~~Corp. ~~Additionally,~~ ifand ~~required by Nasdaq~~Vaporin, ~~the~~Inc. ~~Borrower~~pursuant ~~shall use its best efforts~~ to ~~receive~~which ~~shareholder~~Vaporin, ~~approval of the issuance of shares underlying the note prior to the End Date~~Inc. ~~The~~ ~~number~~will ofmerge ~~shares~~with ~~convertible~~and ~~under~~into ~~the~~Vapor ~~note is limited to 19~~Corp.~~99% of the Borrower’s common stock.~~

Votes For		Votes Against		Abstentions		Broker Non-Votes
4,421,792		3,291		799		—

2.	Approval, on a non-binding advisory basis, of the compensation of the named executive officers of Vaporin, Inc. based on or related to the merger.

Votes For		Votes Against		Abstentions		Broker Non-Votes
4,365,700		40,800		19,382		—

3.	Approval of a proposal to authorize the Board of Directors to adjourn or postpone the special meeting to a later date, if necessary or appropriate, to solicit additional proxies in favor of approval of the merger agreement or to vote on other matters properly before such special meeting.

Votes For		Votes Against		Abstentions		Broker Non-Votes
4,419,001		5,409		1,472		—

The outstanding voting power entitled to vote consisted of 6,543,252 votes.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

VAPORIN, INC.

Date: February 327, 2015 By: /s/ James Martin

Name: James Martin

Title: Chief Financial Officer

Filing Compare · VAPORIN, INC.